Skip to main content
    K

    Kyverna Therapeutics, Inc. Common Stock (KYTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.70
    -0.06 (-1.26%)

    Market Cap: $300.94M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Kyverna Therapeutics, Inc. Common Stock (KYTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Kyverna Therapeutics, Inc. Common Stock (KYTX) has a market cap of $300.94M and an enterprise value of $294.08M. Its share count is up 42.71% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 2.28% below the market cap, as cash exceeds debt.

    Market Cap$300.94M
    Enterprise Value$294.08M
    Latest price (Nov 17, 2026)$4.70

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.75% in the quarter ended Sep 30, 2026 and grew 19.82% a year over 2 years.

    Shares Outstanding61.96M
    Shares Change (YoY)+42.71%
    Shares Change (QoQ)+1.75%
    Share Count Growth (2Y CAGR)+19.82%

    Price Statistics

    The stock is down 31.69% over 52 weeks and trades 22.70% below its 50-day average.

    Beta (1Y)2.25
    52-Week Change-31.69%
    1-Month Change-19.38%
    3-Month Change-47.01%
    6-Month Change-45.98%
    Total Return (1Y)-31.69%
    Return vs SPY (1Y)-51.53%
    Max Drawdown (1Y)-59.02%
    Max Drawdown (3Y)-93.92%
    Sharpe Ratio (1Y)-0.58
    Correlation with SPY (1Y)0.35
    50-Day Average$6.08
    200-Day Average$7.85
    52-Week Range$4.50 to $13.67
    RSI (14 Days)33.9
    Average Volume (20 Days)822.20K

    Price chart

    Financial Position

    Current assets cover 7.01x current liabilities, and total debt is 0.19x shareholder equity.

    Current Ratio7.01x
    Quick Ratio7.01x
    Debt / Equity0.19x
    Interest Coverage-64.94x

    Returns and Efficiency

    Return on invested capital is -81.50% and return on equity is -118.50% over the last 12 months.

    Return on Equity (ROE)-118.50%
    Return on Assets (ROA)-83.30%
    Return on Invested Capital (ROIC)-81.50%
    ROA (5Y Average)-50.20%

    Scores

    KYTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$368.00K
    Operating Income-$163.10M
    Pretax Income-$157.79M
    Net Income-$157.79M
    Reported EPS (TTM)-$2.77

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 70.29% of the $189.44M in total assets.

    Cash and Equivalents$31.82M
    Total Debt$24.96M
    Net Cash$6.86M
    Net Cash Per Share$0.11
    Working Capital$151.12M
    Shareholder Equity$133.15M
    Book Value Per Share$2.15
    Total Assets$189.44M
    Total Liabilities$56.28M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.61M of capital spending, operating cash flow left -$152.41M of free cash flow.

    Operating Cash Flow-$150.80M
    Capital Expenditures$1.61M
    Free Cash Flow-$152.41M
    FCF Per Share-$2.46
    Depreciation and Amortization$3.91M
    Share Repurchases$359.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    KYTX does not pay a dividend. Its free cash flow yield is -52.34%.

    FCF Yield-52.34%
    Buyback Yield-42.76%
    Shareholder Yield-42.76%

    Peer Position

    Against 3 similar companies, KYTX has the lowest ROIC.

    ROIC-81.50% vs -32.76% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -76.37% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About KYTX

    What is KYTX's market cap?

    Kyverna Therapeutics, Inc. Common Stock has a market cap of $300.94M. Its enterprise value, which adds debt and subtracts cash, is $294.08M.

    How many shares of KYTX are outstanding?

    Kyverna Therapeutics, Inc. Common Stock has 61.96M shares outstanding. The count is up 42.71% from a year earlier.

    Does KYTX pay a dividend?

    No. Kyverna Therapeutics, Inc. Common Stock does not pay a dividend.

    How much debt does KYTX have?

    Kyverna Therapeutics, Inc. Common Stock has $24.96M of total debt and $31.82M of cash and equivalents, a net cash position of $6.86M.